TABLE 3.
Comparison of laboratory and radiology results at diagnosis, and outcome, by disease subtype
| Clinical Characteristic | UCD (n=18) |
HHV8-Negative MCD (n=6) |
|---|---|---|
| N (%) [95% CI] or Median (IQR) | ||
| Hemoglobin (g/dL)** | ||
| Normal | 8/15 (53%) [27–79%] |
2/5 (40%) [5–85%] |
| Low | 5/15 (33%) [12–62%] |
3/5 (60%) [15–95%] |
| High | 2/15 (13%) [2–40%] |
0/5 (0%) [0–52%] |
| Hemoglobin Z-score | −0.5 (−2.9, 0.17) | −2.2 (−5.6, −0.53) |
| MCV | ||
| Normal | 11/15 (73%) [45–92%] |
4/5 (80%) [28–99%] |
| Low | 4/15 (27%) [8–55%] |
1/5 (20%) [0.5–72%] |
| MCV Z-score | −1.04 (−2.35, −0.32) | −0.08 (−0.76, 0.08) |
| WBC Count (x103/μL) | 7.6 (5.8, 9.06) | 8.1 (5.0, 9.5) |
| Platelet count (x103/μL) | 330 (294, 401) | 216 (176, 274) |
| CRP Abnormal |
5/10 (50%) [19–81%] |
3/4 (75%) [19–99%] |
| ESR Abnormal |
5/11 (45%) [17–77%] |
1/4 (25%) [0.6–81%] |
| Blood HHV Positive |
0/5 (0%) [0–52%] |
0/5 (0%) [0–52%] |
| Serum IL-6 Abnormal |
2/6 (33%) [4–78%] |
2/4 (50%) [7–93%] |
| Size of largest site (cm3)a | 53.0 (26.6, 71.1) | 14.8 (11.8, 30.4) |
| Size of 2nd largest site (cm3) | NA | 8.7 (6.8, 9.7) |
| Size of 3rd largest site (cm3) | NA | 3.3 (3.2, 4.2) |
| PET SUVmaxb | 3.9 (3.0, 5.2) | 2.6 (2.4, 2.9) |
| Relapse/Progression | 0/10 [0–31%] |
3/6 (50%) [12–88%] |
**
Hemoglobin was categorized using two standard deviations above/below the age and sex adjusted norm
a
Volumetric measurement was available for 12 UCD and all MCD patients.
b
PET SUVmax was available for 7 UCD and 2 MCD patients.
UCD, unicentric Castleman disease; MCD, multicentric Castleman disase; HHV8 human herpes virus-8; CI, confidence interval; IQR, interquartile range; MCV, mean cellular volume; WBC, white blood cell; CRP, C-reactive protein; ESR, erythryocyte sedimentation rate;IL-6, interleukin-6; cm3, cubic centimeters; PET SUVmax, positron emission tomography maximum standardized uptake value